SalioGen Therapeutics is advancing potentially curative therapies using a new category of genetic medicines called Gene Coding. Gene Coding involves adding new genetic code to turn on, off or to modify functions of new or existing genes. This works by using enzymes called Saliogases, proprietary mammalian-derived enzymes that can integrate DNA sequences into defined locations in the genome. Integration, unlike CRISPR-Cas9, does not involve double strand DNA breaks, nor does it rely on host DNA repair pathways, increasing efficiency and reliability. The therapeutic cargo therefore includes two components: RNA that encodes Saliogase and the donor DNA to be integrated. SalioGen aims to apply Gene Coding to cell therapy, stem cell therapy and rapid manufacturing of other biologics.

<p>SalioGen Therapeutics is advancing potentially curative therapies using a new category of genetic medicines called Gene Coding. Gene Coding involves adding new genetic code to turn on, off or to modify functions of new or existing genes. This works by using enzymes called Saliogases, proprietary mammalian-derived enzymes that can integrate DNA sequences into defined locations in the genome. Integration, unlike CRISPR-Cas9, does not involve double strand DNA breaks, nor does it rely on host DNA repair pathways, increasing efficiency and reliability. The therapeutic cargo therefore includes two components: RNA that encodes Saliogase and the donor DNA to be integrated. SalioGen aims to apply Gene Coding to cell therapy, stem cell therapy and rapid manufacturing of other biologics.</p>


SalioGen Therapeutics

Founded: 2020
Location: Cambridge, MA
Employee range: 50 - 200
Clinical stage: RD
Therapy area: Genetic diseases
Drug types: GEN
Lead product: Undisclosed
Funding: $115M B Jan 2022; $20M A Mar 2021

About:

Jobs: